RxDoctor Payments DataLook up a doctor →

Maximo Lama, MD

Critical Care Medicine · Kissimmee, FLNPI 1326276445

Payments from drug & device makers

$254,767in general payments, 2019–2025

Across 1,455 payments — averaging $175.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$206K
  • AstraZeneca$28K
  • Boehringer Ingelheim$3K
  • Actelion Pharmaceuticals US, Inc.$3K
  • Grifols USA, LLC$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • plus $12K from 53 others

What the payments were for

  • Speaking & faculty fees$217,04085%
  • Travel & lodging$1,4871%
  • Food & beverage$35,53614%
  • Education$7040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK354$205,607
AstraZeneca285$28,262
Boehringer Ingelheim157$3,226
Actelion Pharmaceuticals US, Inc.83$2,728
Grifols USA, LLC71$1,810
Regeneron Healthcare Solutions, Inc.41$1,089
Takeda Pharmaceuticals U.S.A., Inc.56$1,056
Sanofi47$973
Jazz Pharmaceuticals Inc.12$958
United Therapeutics Corporation18$925
Philips North America LLC43$802
Mylan Specialty L.p.45$798
Insmed, Inc.30$641
Amgen17$615
Genentech USA, Inc.25$483
Harmony Biosciences LLC9$421
Bayer12$324
Paratek Pharmaceuticals, Inc.6$316
Sunovion Pharmaceuticals Inc.14$310
Novartis18$292
AbbVie4$235
Axsome Therapeutics, Inc.8$231
Vapotherm Inc3$203
Merck8$195
ZOLL Respicardia, Inc.1$188
Pulmonx Corporation3$181
Mallinckrodt Hospital Products Inc.2$171
E.r. Squibb & Sons, L.L.C.4$155
Verona Pharma, Inc.11$149
Idorsia Pharmaceuticals US Inc3$130
Inspire Medical Systems, Inc.2$126
Electromed, Inc.11$94
Vifor Pharma, Inc.4$94
ANI Pharmaceuticals, Inc.3$92
Teva Pharmaceuticals USA, Inc.6$91
Johnson & Johnson(2 entities)5$89
Sanofi-aventis U.S. LLC1$89
Portola Pharmaceuticals, LLC2$88
Pfizer3$66
Tactile Systems Technology Inc2$41
Lilly USA, LLC2$37
Inogen, Inc.2$37
Greer Laboratories, Inc.2$29
Shire North American Group Inc2$28
Advanced Respiratory, Inc2$27
Avadel CNS Pharmaceuticals, LLC1$26
Alk-abello, Inc2$26
Circassia Inc.2$25
Sandoz1$24
Viatris Specialty LLC1$23
Fisher & Paykel Healthcare Inc1$19
Baxter Healthcare1$19
Optinose US, Inc.1$19
Hikma Pharmaceuticals USA1$17
Biogen1$16
Resmed Corp1$16
Boston Scientific1$13
Phadia US Inc.1$13
Nabriva Therapeutics, PLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$254,767 in reported general payments places this provider in the 95th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$334,493
Medicare patients
593
Services billed
9,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter1,129$869,066
OfevNintedanib Esylate46$515,468
AdempasRiociguat24$323,925
OpsumitMacitentan21$245,953
XyremSodium Oxybate11$236,672
Breztri AerosphereBudesonide/Glycopyr/Formoterol343$227,768
TezspireTezepelumab-Ekko53$220,304
Breo ElliptaFluticasone/Vilanterol262$128,124
Stiolto RespimatTiotropium Br/Olodaterol Hcl104$63,355
SymbicortBudesonide/Formoterol Fumarate212$58,242
NucalaMepolizumab14$58,106
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr121$55,525
Spiriva RespimatTiotropium Bromide79$49,812
Albuterol Sulfate HfaAlbuterol Sulfate870$20,875
EliquisApixaban22$16,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta$205,607$1,132,9011,586 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$3,226$634,264240 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort$28,262$506,315608 claims
BayerAdempas$324$323,92524 claims
Actelion Pharmaceuticals US, Inc.Opsumit$2,728$245,95321 claims
PfizerEliquis$66$16,45322 claims
MerckDulera$195$8,03111 claims
Hikma Pharmaceuticals USAEpinephrine$17$2,21720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 618 critical care medicine providers in Florida.

Other critical care medicine in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →